title: Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia.
authors: Division of Hematology/Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York2New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York.
authors: Joseph G
authors: JG
authors: Jurcic
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D058990:Molecular Targeted Therapy / Q000379:methods*; D009154:Mutation; D010880:Piperidines / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D001562:Benzimidazoles; D019086:Bridged Bicyclo Compounds, Heterocyclic; D010880:Piperidines; D013449:Sulfonamides; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; C577197:crenolanib; C579720:venetoclax